PixCell Medical Expands HemoScreen Access Across Canada
Yokneam Illit, Israel, September 2, 2026 PixCell Medical has expanded its international presence into Canada through a strategic partnership...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Yokneam Illit, Israel, September 2, 2026 PixCell Medical has expanded its international presence into Canada through a strategic partnership...
Hamburg, Germany, and Sydney, Australia, September 2, 2026 Evotec SE and Plectonic Biotech have entered into a research collaboration...
Irvine, California, USA, September 1, 2026 SkinMedica, part of Allergan Aesthetics, an AbbVie company, has expanded its regenerative skincare...
DURHAM, N.C., Aug 26, 2026 Priovant Therapeutics announced the publication of skin-specific outcomes from the Phase 3 VALOR trial...
West Chester, Pa. – August 27, 2026 Verrica Pharmaceuticals announced completion of enrollment in COVE-2, the first pivotal Phase...
FOSTER CITY, Calif. — August 25, 2026 Sagimet Biosciences announced that its AURORA Phase 3 clinical trial of denifanstat...
Washington, D.C., August 24, 2026 Vanda Pharmaceuticals Inc. announced that the European Commission has granted Orphan Designation to imsidolimab...
Shanghai and Hong Kong, PRC, August 24, 2026 Antengene Corporation Limited has reported its first-ever profitable period, alongside continued...
Shanghai, China,August 20, 2026 Henlius announced its 2026 interim results, highlighting continued financial growth, expanding global commercialization, and progress...
Needham, Massachusetts, USA,August 20, 2026 Evolved By Nature, Inc. announced that its programmable peptide platform has been used in...
